StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.8.3
  1. Startseite
  2. /Verbindung

Perindopril

HCID 107807
Neue Reaktion
Drucken
GrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung
TeilstruktursucheÄhnliche Strukturen suchen

Grundinformationen

CAS
107133-36-8
Standard-SMILES
CCC[C@H](N[C@@H](C)C(=O)N1[C@H](C(=O)O)C[C@@H]2CCCC[C@@H]21)C(=O)OCC
InChIKey
IPVQLZZIHOAWMC-QXKUPLGCSA-N
Summenformel
C19H32N2O5
Durchschnittliche Molmasse
368,5 g/mol
Monoisotopische Masse
368,23112213

Überblick

Perindopril is an alpha-amino acid ester that is the ethyl ester of N-{(2S)-1-[(2S,3aS,7aS)-2-carboxyoctahydro-1H-indol-1-yl]-1-oxopropan-2-yl}-L-norvaline. It has a role as an EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor and an antihypertensive agent. It is an ethyl ester, an organic heterobicyclic compound, a dicarboxylic acid monoester and an alpha-amino acid ester. It is a conjugate acid of a perindopril(1-).

Namen und Bezeichner

Bevorzugter Name
Perindopril
IUPAC
(2S,3aS,7aS)-1-[(2S)-2-[[(2S)-1-ethoxy-1-oxopentan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid
Englischer Name
Perindopril erbumine
Summenformel
C23H43N3O5
Molmasse
441.61

Namen und Synonyme

PERINDOPRIL82834-16-0PerindoprilumMcN-A-2833S-9490DTXSID6023440Y5GMK36KGYCHEBI:8024DTXCID303440(2S,3aS,7aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxopentan-2-yl]amino}propanoyl]octahydro-1H-indole-2-carboxylic acidPirindopril(2S,3aS,7aS)-1-((S)-N-((S)-1-Carboxybutyl)alanyl)hexahydro-2-indolinecarboxylic acid, 1-ethyl ester
Weitere Namen anzeigen
Aceonprindopril APIPerindopril ErbuMine (Aceon)Perindopril t-ButylaMinePerindopril tert-butylamine saltPerindopril for stereochemical purity CRSCoversuMPrestariuMPerindorilPerinodopril
(2S,3aS,7aS)-1-[(2S)-2-{[(2S)-1-ethoxy-1-oxopentan-2-yl]amino}propanoyl]-octahydro-1H-indole-2-carboxylic acidS 9490Erbumine, Perindopril1H-Indole-2-carboxylic acid, 1-(2-((1-(ethoxycarbonyl)butyl)amino)-1-oxopropyl)octahydro-, (2S-(1(R*(R*)),2alpha,3abeta,7abeta))-S9490(2S,3aS,7aS)-1-((2S)-2-(((2S)-1-ethoxy-1-oxopentan-2-yl)amino)propanoyl)-octahydro-1H-indole-2-carboxylic acid(2S,3aS,7aS)-1-((2S)-2-(((2S)-1-ethoxy-1-oxopentan-2-yl)amino)propanoyl)octahydro-1H-indole-2-carboxylic acid(2S,3aS,7aS)-1-[(S)-N-[(S)-1-Carboxybutyl]alanyl]hexahydro-2-indolinecarboxylic acid, 1-ethyl ester

Eigenschaften

Berechnete Struktureigenschaften

XLogP
0,9
Polarare Oberfläche (TPSA)
95,9 Ų
H-Brücken-Donoren
2
H-Brücken-Akzeptoren
6
Frei drehbare Bindungen
9
Schwere Atome
26
Formalladung
0
Komplexität
524

Experimentelle und physikochemische Eigenschaften

Drugs · 3 Einträge

Pharmaceuticals -> Listed in ZINC15

Pharmaceuticals -> Antihypertensives

Pharmaceuticals -> Used in Switzerland

LogP2.6
Solubility1.22e+00 g/L
Human Drugs · 2 Einträge

Breast Feeding; Lactation; Milk, Human; Antihypertensive Agents; Angiotensin-Converting Enzyme Inhibitors; ACE Inhibitors

Pharmaceuticals

Physical DescriptionSolid
Collision Cross Section189.7 Ų [M+H]+ [CCS Type: DT; Buffer gas: N2; Ionization: ESI+; Dataset: TOXCAST; Source Identifier: DTXSID1044198]

Physikochemische Eigenschaften

Schmelzpunkt
126 · 126-128°C
storage temp.
2 · 2-8°C
Löslichkeit
2 O: · H2O: soluble10mg/mL, clear

Sicherheit und Regulatorisches

Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.

GHS-Klassifizierung

GHS Classification · 4 Einträge

Danger

H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation]

P203, P260, P261, P264+P265, P271, P280, P304+P340, P305+P351+P338, P318, P319, P337+P317, P403+P233, P405, and P501 (click each P-code to see the statement)

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

Gefahrenhinweise

Hazard Classes and CategoriesEye Irrit. 2 (100%)

Toxikologische Informationen

HepatotoxicityPerindopril, like other ACE inhibitors, has been associated with a low rate of serum aminotransferase elevations (
Drug Induced Liver Injury · 5 Einträge

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

perindopril

DILI Negative

Oral

DOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation
EPA Human Health Benchmarks for Pharmaceuticals · 6 Einträge

Perindopril

0.1

0.4

The usual maintenance dose range is 4 mg to 8 mg administered as a single daily dose or in two divided doses.

Data used to generate the benchmarks include the following: Lowest Daily Dose (LDD): 4 mg/day, Lowest Therapeutic Dose (LTD): 0.1 mg/kg-day, and Screening Dose: 0.00002 mg/kg-day.

Chemie und Industrie

Pharmakologische Informationen

ATC Code · 3 Einträge

C09AA04

C - Cardiovascular system

QC - Cardiovascular system

Protein BindingPerindoprilat, 10-20% bound to plasma proteins
Pharmacodynamics · 1 Eintrag

Perindopril is a nonsulfhydryl prodrug that is metabolized via first pass effect (62%) and systemic hydrolysis (38%) to perindoprilat, its active metabolite, following oral administration. Perindoprilat lowers blood pressure by antagonizing the effect of the RAAS. The RAAS is a homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. During sympathetic stimulation or when renal blood pressure or blood flow is reduced, renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is subsequently cleaved to ATII by ACE. ATII increases blood pressure using a number of mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of nephrons where it increases sodium and water reabsorption by increasing the number of sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) from the posterior pituitary gland. ADH stimulates further water reabsorption from the kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT and collecting tubules. Third, ATII increases blood pressure through direct arterial vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. In addition to these major effects, ATII induces the thirst response via stimulation of hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the deactivation of bradykinin increases bradykinin levels and may sustain the effects of perindoprilat by causing increased vasodilation and decreased blood pressure.

Mechanism of Action · 1 Eintrag

Zugehörige Reaktionen

21
Reaktionsaufzeichnung erstellen
Reaktionsgleichung von HRID 273473
HRID 273473als Edukt
Reaktionsgleichung von HRID 273475
HRID 273475als Edukt
Reaktionsgleichung von HRID 273477
HRID 273477als Produkt
Reaktionsgleichung von HRID 273480
HRID 273480als Produkt
Reaktionsgleichung von HRID 273482
HRID 273482als Produkt
Reaktionsgleichung von HRID 900395
HRID 900395als Produkt
Reaktionsgleichung von HRID 1013436
HRID 1013436als Edukt
Reaktionsgleichung von HRID 1180213
HRID 1180213als Produkt
ZurückSeite 1 von 3

Notizen zur Verbindung

Auf dieser SeiteGrundinformationenÜberblickNamen und BezeichnerEigenschaftenSicherheit und RegulatorischesChemie und IndustrieZugehörige ReaktionenNotizen zur Verbindung

Datenbank-Bezeichner

CAS
107133-36-8、82834-16-0
PubChem CID
107807
DTXSID
DTXSID6023440
ChEMBL
CHEMBL1581
ChEBI
CHEBI:8024
UNII
Y5GMK36KGY
EC Number
617-394-0
Nikkaji
J23.744B
Aggregatzustand
powder
Farbe
White
Major Application
pharmaceutical (small molecule)
InChIKey
IYNMDWMQHSMDDE-FEWFLNQGNA-N
SMILES
C(N)(C)(C)C.C(N1[C@@H](C[C@]2([H])CCCC[C@]12[H])C(=O)O)(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC |&1:7,9,15,21,24,r|

13-Sep-19

Sicherheitsdaten

wgk
3
hs_code
2933999552
RTECS-Nr.
NL5999600
risk_code
36/37/38
hazard_code
Xi
safety_code
26-36
Speicherklasse
11 - Combustible Solids
Hazard Classifications
Repr. 2

There are two isoforms of ACE: the somatic isoform, which exists as a glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, which has a lower molecular mass and is thought to play a role in sperm maturation and binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active domains, N and C, which arise from tandem gene duplication. Although the two domains have high sequence similarity, they play distinct physiological roles. The C-domain is predominantly involved in blood pressure regulation while the N-domain plays a role in hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and inhibit the activity of both domains, but have much greater affinity for and inhibitory activity against the C-domain. Perindoprilat, the active metabolite of perindopril, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by inhibiting the pressor effects of ATII as described in the Pharmacology section above. Perindopril also causes an increase in plasma renin activity likely due to a loss of feedback inhibition mediated by ATII on the release of renin and/or stimulation of reflex mechanisms via baroreceptors.

Biological Half-LifePerindopril, 1.2 hours; Peridoprilat, 30-120 hours. The long half life of peridoprilat is due to its slow dissociation from ACE binding sites.
Metabolism/Metabolites · 2 Einträge

Extensively metabolized, with only 4-12% of the dose recovered in urine following oral administration. Six metabolites have been identified: perindoprilat, perindopril glucuronide, perindoprilat glucuronide, a perindopril lactam, and two perindoprilat lactams. Only perindoprilat is pharmacologically active. Peridoprilat and perindoprilat glucuronide are the two main circulating metabolites.

Perindopril has known human metabolites that include Perindoprilat glucuronide.

FDA Pharmacological Classification · 5 Einträge

Y5GMK36KGY

PERINDOPRIL

Established Pharmacologic Class [EPC] - Angiotensin Converting Enzyme Inhibitor

Mechanisms of Action [MoA] - Angiotensin-converting Enzyme Inhibitors

Perindopril is an Angiotensin Converting Enzyme Inhibitor. The mechanism of action of perindopril is as an Angiotensin-converting Enzyme Inhibitor.

MeSH Pharmacological Classification · 2 Einträge

A class of drugs whose main indications are the treatment of hypertension and heart failure. They exert their hemodynamic effect mainly by inhibiting the renin-angiotensin system. They also modulate sympathetic nervous system activity and increase prostaglandin synthesis. They cause mainly vasodilation and mild natriuresis without affecting heart rate and contractility.

Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.

Absorption, Distribution and Excretion · 3 Einträge

Rapidly absorbed with peak plasma concentrations occurring approximately 1 hour after oral administration. Bioavailability is 65-75%. Following absorption, perindopril is hydrolyzed to perindoprilat, which has an average bioavailability of 20%. The rate and extent of absorption is unaffected by food. However, food decreases the extent of biotransformation to peridoprilat and reduces its bioavailability by 35%.

Perindopril is extensively metabolized following oral administration, with only 4 to 12% of the dose recovered unchanged in the urine.

219 - 362 mL/min [oral administration]

Cellular LocationsCytoplasm
Metabolite PathwaysPerindopril Action Pathway

Verwendung und Herstellung

UsesUse (kg; approx.) in Germany (2009): >100
Use ClassificationPharmaceuticals

Anwendungen

VerwendenAn angiotensin-converting enzyme (ACE) inhibitor. Antihypertensive.

Vor- und nachgelagerte Produkte

Vorgelagerte Rohstoffe

DicyclohexylcarbodiimidSchwefelsureRhodiumThionyldichloridNatriumhydroxidIndol-2-carbonsureWasserstoffNorvalinN,N-DiethylethanaminBrenztraubensurePalladiumdihydroxid1-HydroxybenzotriazolToluol-4-sulfonsure

Nachgelagerte Produkte

Perindoprilat